Glenmark Pharmaceuticals on Monday said it was the first pharmaceutical firm to launch in India an intravenous injection formulation, Akynzeo, for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
Glenmark Pharmaceuticals Ltd is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of CINV, under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn